Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?—a population-level analysis

BACKGROUND: Androgen deprivation therapy (ADT), commonly delivered via a luteinizing hormone-releasing hormone (LHRH) agonist, is the standard treatment for advanced prostate cancer (PC). While quite effective, it has been associated with an increased risk of major adverse cardiovascular events (MAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dymanus, Kyle, Friedrich, Nadine A., Howard, Lauren E., Oyekunle, Taofik, De Hoedt, Amanda M., Labadzhyan, Artak, Polascik, Thomas, Klaassen, Zachary, Freedland, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643384/
https://www.ncbi.nlm.nih.gov/pubmed/37969776
http://dx.doi.org/10.21037/tau-23-114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643384/
https://www.ncbi.nlm.nih.gov/pubmed/37969776
http://dx.doi.org/10.21037/tau-23-114

Ejemplares similares